|

Mezigdomide Clinical Trials

10 actively recruiting trials across 7 locations

Also known as: BMS 986348, BMS-986348, BMS986348, CC 92480, CC-92480, CELMoD CC-92480, Cereblon E3 Ligase Modulation Drug CC-92480, Cereblon E3 Ubiquitin Ligase Modulating Agent CC-92480, Cereblon Modulator CC-92480

Birmingham, Alabama2 trials

A Study to Determine the Recommended Dose and Schedule, and Evaluate the Safety and Preliminary Efficacy of Mezigdomide in Combination With Elranatamab in Participants With Relapsed and/or Refractory Multiple Myeloma

University of Alabama at Birmingham

Phase 1/2
A Study to Evaluate the Safety, Effectiveness and Tolerable Dose of Arlocabtagene Autoleucel (BMS-986393) in Novel Combinations in Participants With Relapsed and/or Refractory Multiple Myeloma

University of Alabama at Birmingham

Phase 1

Duarte, California2 trials

A Study of Revumenib and Mezigdomide in People With Leukemia

City of Hope Cancer Center (Data collection only)

Phase 1/2
Mezigdomide (CC-92480) Post Idecabtagene Vicleucel in Treating Patients With Relapsed Multiple Myeloma

City of Hope Medical Center

Phase 1

Other1 trial

Mezigdomide and Elranatamab for Relapsed and/or Refractory Multiple Myeloma
Phase 1/2

Gilbert, Arizona1 trial

Selinexor and Backbone Treatments of Multiple Myeloma Patients

Banner MD Anderson Cancer Center

Phase 1/2

Los Alamitos, California1 trial

A Study to Evaluate Mezigdomide, Bortezomib and Dexamethasone (MEZIVd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)

Cancer and Blood Specialty Clinic

Phase 3

Basking Ridge, New Jersey1 trial

A Study of Teclistamab and Mezigdomide in People With Multiple Myeloma

Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities)

Phase 1

Buffalo, New York1 trial

Mezigdomide, Carfilzomib, and Dexamethasone for the Treatment of Relapsed or Refractory Multiple Myeloma in Patients With Extramedullary Disease

Roswell Park Cancer Institute

Phase 2

Columbus, Ohio1 trial

Elotuzumab, CC-92480, and Dexamethasone for the Treatment of Relapsed or Refractory Myeloma After CD38- and BCMA-Targeted Therapies

Ohio State University Comprehensive Cancer Center

Phase 1

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.